Phase 3 randomized double-blind placebo-controlled study of brivaracetam as adjunctive therapy for focal seizures

Phase 3, randomised, double-blind trial in Focal Onset Epilepsy and Focal onset seizure comparing Brivaracetam add-on with Placebo add-on (2 arms). Primary endpoint: Percent reduction versus placebo in focal seizure frequency per 28 days during the 12-week double-blind treatment period. Started Sep 2024; status: active.